

ANNEX I

**LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL
PRODUCTS, ROUTES OF ADMINISTRATION, APPLICANTS, MARKETING
AUTHORISATION HOLDERS IN THE MEMBER STATES**

Member State EU/EEA	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration
Austria	Novartis Pharma GmbH Stella-Klein-Löw-Weg 17 A 1020 Wien Austria	Cardioxane 500 mg - Pulver zur Herstellung einer Infusionslösung	500 mg	Powder for solution for infusion	Intravenous use
Austria	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	Cyrdanax 20 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung	20 mg	Powder for solution for infusion	Intravenous use
Austria	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	Enaxozar 20 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung	20 mg	Powder for solution for infusion	Intravenous use
Czech Republic	Novartis s.r.o. GEMINI, budova B Na Pankráci 1724 / 129 CZ-140 00 Praha 4 Czech Republic	Cardioxane	500 mg	Powder for solution for injection	Intravenous use
Czech Republic	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	Cyrdanax 20 mg/ml prášek pro přípravu infuzního roztoku	20 mg	Powder for solution for injection	Intravenous use
Germany	Novartis Pharma GmbH Roonstr. 25 D-90429 Nürnberg Germany	CARDIOXANE 500 mg, Pulver zur Herstellung einer Infusionslösung	500 mg	Powder for solution for infusion	Intravenous (not otherwise specified)

Member State EU/EEA	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration
Germany	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	Cyrdanax 20 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung	20 mg	Powder for solution for injection	Intravenous use
Germany	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	Enaxozar 20 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung	20 mg	Powder for solution for injection	Intravenous use
Denmark	Novartis Healthcare A/S, Lyngbyvej 172 DK-2100 Copenhagen Ø Denmark	Cardioxane	500 mg	Powder for solution for infusion	Intravenous use
Greece	NOVARTIS (HELLAS) A.E.B.E. 12km National Highway No1 Metamorfosi Attikis 14451 Greece	CARDIOXANE	500 mg/vial	Powder for solution for infusion	Intravenous use
Spain	NOVARTIS FARMACEUTICA, S.A.Gran Via de les Corts Catalanes, 764 08013 Barcelona Spain	CARDIOXANE 500 mg polvo para solucion para perfusion	500 mg	Powder for solution for infusion	Intravenous use
Finland	Novartis Finland Oy, Metsänneidonkuja 10 02130 Espoo Finland	Cardioxane	500 mg	powder for solution for infusion	Intravenous use

Member State EU/EEA	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration
France	NOVARTIS PHARMA SAS 2-4, rue Lionel Terray 92500 Rueil-Malmaison FRANCE	CARDIOXANE 500 mg, poudre pour solution pour perfusion	500 mg	powder for solution for infusion	Intravenous use
France	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	DEXRAZOXANE CYATHUS 20 mg/ml, poudre pour solution pour perfusion	20 mg	Powder for solution for injection	Intravenous use
Hungary	Novartis Hungária Kft. Pharma részlege Bartók Béla út 43-47. (Bartók-Ház, V. em.) 1114 Budapest Hungary	CARDIOXANE	500 mg	Powder for solution for infusion	Intravenous use
Hungary	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	Procard 20 mg/ml Por oldatos infúzióhoz	20 mg	Powder for solution for injection	Intravenous use

Member State EU/EEA	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration
Ireland	MAH: Novartis Pharmaceuticals UK, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR United Kingdom Mailing address: Novartis Ireland Ltd Beech House, Beech Hill Office Campus Clonskeagh Dublin 4 Ireland	Cardioxane	500 mg	Powder for solution for infusion	Intravenous use
Italy	Novartis Farma spa Largo Umberto Boccioni, 121040 Origgio- Varese Italy	CARDIOXANE	500 mg	powder for solution for infusion	Intravenous use
Lithuania	Novartis Finland Oy Metsänneidonkuja 10 FI-02130 Espoo Finland	Cardioxane	500 mg	Powder for solution for infusion	Intravenous use
Luxembourg	NOVARTIS PHARMA GMBH 25 ROONSTRASSE 90429 NUERNBERG Germany	CARDIOXANE	500 mg	POWDER FOR SOLUTION FOR INFUSION	Intravenous use
Netherlands	Novartis Pharma B.V. Raapopseweg 1 6824 DP ARNHEM The Netherlands	Cardioxane 500 mg	500 mg	powder for solution for infusion	Intravenous use

Member State EU/EEA	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration
Norway	Novartis Norge AS Postboks 237 Okern 0510 Oslo Norway	Cardioxane	500 mg	Powder for solution for infusion	injection
Poland	Novartis Pharma GmbH Roonstarsse 25 D-90429 Nürnberg Germany	Cardioxane	500 mg	powder for solution for infusion	Intravenous use
Portugal	Novartis Farma - Produtos Farmacêuticos, S.A. Rua do Centro Empresarial, Edifício 8, Quinta da Beloura 2710-444 Sintra Portugal	Cardioxane	500 mg	powder for solution for infusion	Intravenous use
Romania	CYATHUS EXQUIRERE Pharmaforschungs GmbH Rudolfsplatz 2/8 1010 Wien Austria	CYRDANAX 20 mg/ml	20 mg/ml	powder for solution for infusion	Intravenous use
Slovakia	Novartis s.r.o. GEMINI, budova B Na Pankráci 1724 / 129 CZ-140 00 Praha 4 Czech Republic	CARDIOXANE	500 mg	powder for solution for infusion	Intravenous use

Member State EU/EEA	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration
United Kingdom	Novartis Pharmaceuticals UK Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom	Cardioxane	500 mg	powder for solution for infusion	Intravenous use